The device was first used in gastric sleeve surgery Aug. 24, 2021, and Standard Bariatrics said Jan. 19 that surgeons using it are reporting less operative time and less postoperative patient nausea. It was cleared by the FDA in April 2021.
Standard Bariatrics said the Titan SGS reached $1 million in sales during November 2021, after less than six months on the market. Standard Bariatrics currently has multiple investors with a mix of series A and series B funding.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
